KRAS and non-small cell lung carcinoma: The lower potency of afatinib in NSCLC lines harbouring mutated KRAS was also observed by other investigators (Cha et al. 2012), while other studies revealed that the presence of mutated KRAS had only a little effect on the potency of afatinib in inhibiting proliferation and activate caspase-7, a marker of apoptosis induction (Chen et al. 2012).